Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia

Hyejin Shin, Jung-Eun Ha, Dae Young Zang, MDPhD, Sung-Hyun Kim, MD PhD, Young Rok Do, PhDMD, Won Sik Lee, MD PhD, Soo-Hyun Kim, Kyung-Mi Kee, Seon-Young Yang, So-Yoon Hwang, Eun-Jung Jang, Jangik Lee, PharmD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-140626

Published: 2020

Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139253

Published: 2020

Journal Articles

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ho-Sup Lee, MD PhD, Sung-Soo Yoon, MD PhD, Dong-Yeop Shin, MD PhD, Ja Min Byun, Je-Jung Lee, MD PhD, Sung-Hoon Jung, MD, Chang-Ki Min, MD PhD, Hyo Jung Kim, MD PhD, Byeong Seok Sohn, MD PhD, Sung Hwa Bae, MD, Lee Gyeong-Won, Sungwoo Park, MD, Young Rok Do, PhDMD, Hyun Jung Lee, MD, Min Kyoung Kim, Yoo Jin Lee, MD PhD

Blood (2019) 134 (Supplement_1): 4372.

https://doi.org/10.1182/blood-2019-127707

Published: 2019

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Seok Jae Huh, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Won-Sik Lee, Yoojin Lee, MD PhD, Ho Sup Lee, MD

Blood (2018) 132 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2018-99-119473

Published: 2018

Journal Articles

High Incidence of Hepatitis B Viral Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Jieun Uhm, MD PhD, Sung-Hyun Kim, MD PhD, Sukjoong Oh, MD PhD, Dae Young Zang, MD PhD, Young Rok Do, PhD MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Sung-Eun Lee, MD PhD, Dong-Wook Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3010.

https://doi.org/10.1182/blood-2018-99-117543

Published: 2018

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

Long-Term Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Patients with Active Cancer in a Prospective Multicenter Trial: KVTE13-01

Ho-Young Yhim, MD, Won-Il Choi, MD, Sung-Hyun Kim, MD PhD, Seung-Hyun Nam, MD, Kyoung Ha Kim, Yeung-Chul Mun, MD PhD, Hun-Gyu Hwang, MD, Doyeun Oh, MD, Keun-Wook Lee, MD, Eun-Kee Song, MD, Yong Shik Kwon, MD, Soo-Mee Bang, MD PhD

Blood (2017) 130 (Supplement 1): 3711.

https://doi.org/10.1182/blood.V130.Suppl_1.3711.3711

Published: 2017

Journal Articles

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

Sukjoong Oh, Ki Hoon Kang, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2864.

https://doi.org/10.1182/blood.V130.Suppl_1.2864.2864

Published: 2017

Journal Articles

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Sung-Eun Lee, MD, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, Yeung-Chul Mun, MD PhD, Young-Woong Won, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2873.

https://doi.org/10.1182/blood.V130.Suppl_1.2873.2873

Published: 2017

Journal Articles

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Blood (2017) 130 (Supplement 1): 3130.

https://doi.org/10.1182/blood.V130.Suppl_1.3130.3130

Published: 2017

Journal Articles

Bleeding Complications in CAT Patients Treated with LMWH or DOACs

Kyoung Ha Kim, Ho-Young Yhim, MD, Won-Il Choi, Sung-Hyun Kim, MD PhD, Yeung-Chul Mun, MD PhD, Soo-Mee Bang, MD PhD, Doyeun Oh, MD, Ji Hyun Lee, MD PhD, Ji Yun Lee, MD

Blood (2017) 130 (Supplement 1): 4914.

https://doi.org/10.1182/blood.V130.Suppl_1.4914.4914

Published: 2017

Journal Articles

Blinatumomab Treatment in Korean Adult Patients with Relapse/Refractory Acute Lymphoblastic Leukemia

Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Jae-Ho Yoon, MD PhD, Seok Lee, MD PhD, Dae Sik Kim, MD PhD, Se Ryun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Soo-Mee Bang, MD PhD, Youngil Koh, MD, Ho-Young Yhim, MD, Sang Kyun Sohn, MDPhD, Ik-Chan Song, MD, Hong-ghi Lee, MD PhD, June-Won Cheong, MDPhD, Yunsuk Choi, MD, Ho-Jin Shin, MD PhD

Blood (2017) 130 (Supplement 1): 5004.

https://doi.org/10.1182/blood.V130.Suppl_1.5004.5004

Published: 2017

Journal Articles

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Won-Sik Lee, MD PhD, Hye-Young Song, Hyeoung-Joon Kim, Jee Hyun Kong, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Yunsuk Choi, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 1593.

https://doi.org/10.1182/blood.V130.Suppl_1.1593.1593

Published: 2017

Journal Articles

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Blood (2017) 130 (Supplement 1): 5075.

https://doi.org/10.1182/blood.V130.Suppl_1.5075.5075

Published: 2017

Journal Articles

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

Blood (2017) 130 (Supplement 1): 4257.

https://doi.org/10.1182/blood.V130.Suppl_1.4257.4257

Published: 2017

Journal Articles

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Blood (2014) 124 (21): 3155.

https://doi.org/10.1182/blood.V124.21.3155.3155

Published: 2014

Journal Articles

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Soo Young Choi, Sung-Eun Lee, Yun jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, MD, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 1816.

https://doi.org/10.1182/blood.V124.21.1816.1816

Published: 2014

NARROW

Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness

High Incidence of Hepatitis B Viral Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Long-Term Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Patients with Active Cancer in a Prospective Multicenter Trial: KVTE13-01

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Bleeding Complications in CAT Patients Treated with LMWH or DOACs

Blinatumomab Treatment in Korean Adult Patients with Relapse/Refractory Acute Lymphoblastic Leukemia

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only